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The results of an open-label, randomized, Phase III trial 
of r-methionyl human granulocyte-colony-stimulating fac- 
tor (r-metHuG-CSF) in 41 patients with severe chronic neu- 
tropenia (SCN) are reported. Patients with diagnoses of con- 
genital, cyclic, and idiopathic neutro~nia, with histories of 
recurrent infections, were evaluated. The primary objective 
of the trial was to evaluate the ability of r-metHuG-CSF to 
increase the ANC to >1500/mm3. A secondary objective was 
to evaluate variables associated with infection-related mor- 
bidity in SCN. r-metHuG-CSF treatment consisted of 1 
month of dose titration followed by 4 months of treatment at 
an optimal dose. Patients were randomized to either imme- 
diate treatment with r-metHuG-CSF (Group A) or four 
months of obse~ation followed by r-metHuG-CSF treat- 
ment (Group B). r-metHuG-CSF was administered by daily, 
subcutaneous injection with initial doses of 3 to 10 pgikgl 
day. Forty of 41 patients who received r-metHuG-CSF had a 
complete response (median ANC >1500/mm3 during 4 
months of r-metHuG-CSF treatment). All cases of gingivitis 
and severe mouth ulcers resolved upon treatment with 
r-met&G-CSF. Serious infections were also eliminated. 
Only one patient failed to show clinical improvement in re- 
sponse to r-metHuG-CSF treatment. Adverse reactions dur- 
ing the tlrst 5 months of treatment were mild. Spienomegaly 
(mild) was noted in some patients. The administration of 
r-metHuG-CSF in patients with SCN significantly increased 
the ANC (P < 0.001) and was accompanied by a marked 
reduction in infectious complications. 0 1992 Academic press, Inc. 
INTRODUCTION 
The myeloid growth factors are glycoprotein hor- 
mones that regulate the proliferation and differentia- 
tion of myeloid progenitor cells and the function of ma- 
ture blood cells (1). Several of these factors have been 
molecularly characterized and produced for clinical ap- 
pliction via recombinant DNA technology. In particu- 
’ Presented as part of a symposium entitled “Future Directions of 
Cytokine and Immunoglobulin Therapy,” January ll-12,1991, Tue- 
son, AZ. 
’ To whom correspondence should be addressed at Pediatric He- 
matology/Oncology, C. S. Mott Children’s Hospital, Room F 6515, 
Box 0238, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. 
lar granulocyt+macrophage colony-stimulating factor 
(GM-CSF), granulocyte-colony-stimulating factor (G- 
CSF), macrophage-colony-stimulating factor (M-CSF), 
and interleukin-3 (IL-3) have been developed as poten- 
tial therapeutic agents, and their effects on myelopoie- 
sis and mature blood cell function are currently under 
active investigation. 
The major cellular sources of the myeloid-eolony- 
stimulating factors are T lymphocytes, monocytes, 
macrophages, endothelial cells, and fibroblasts (Table 
1) (2,3). GM-CSF is produced by each of these sources 
only after cell activation (4). Similarly, G-CSF is pro- 
duced by mononuclear cells in increased amounts 
along with interleukin-2 (IL-2) and tumor necrosis fac- 
tor (TNF) following cell activation. IL-3 and TNF also 
induce fibroblasts and endothelial cells to produce 
G-CSF (5, 6). Unlike GM-CSF, G-CSF levels circulate 
in the plasma in acute infection which may lead to an 
increase in the absolute neutrophil count (ANC) (7). 
IL-3 is produced almost exclusively by activated T 
cells. M-CSF is constitutively produced by many cells 
and circulates in plasma in detectable concentrations 
sutlicient for humoral action (8). Because the CSFs can 
activate macrophages, the elaboration of one hemato- 
poietic growth factor can lead to the production of oth- 
ers (9). The precise roles of the myeloid-colony- 
stimulating factors in the physiologic regulation of 
steady-state myelopoiesis have not been fully ascer- 
tained, but during infection circulating G-CSF may 
contribute to elevating the ANC (10). 
The biologic effects of the colony-stimulating factors 
are mediated via binding to high-affinity specific recep- 
tors on the surface of target cells which include the 
myeloid precursor cells (Tables 1 and 2). The overlap in 
action of GM-CSF and IL-3 is paralleled by an overlap 
in the expression of the different receptors on target 
cells. Low numbers of high- and low-affinity GM-CSF 
receptors are expressed by neutrophils, eosinophils, 
and monocytes (Table 1) (11, 12). High-affinity recep- 
tors for IL-3 are present on eosinophils, basophils, and 
monocytes but not on neutrophils (13,14). Thus, these 
two factors have pleotropic effects in terms of stimulat- 
ing multiple cell lineages. In contrast, high-affinity 
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Note. Adapted from Ref. (2). 
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of the kidney, 
Kupffer cells 
functional receptors for G-CSF are expressed mainly 
by neutrophils and to a lesser extent by monocytes (15, 
16). The M-CSF receptor has been identified as the 
product of the cellular proto-oncogene c-fms and is 
found on the cells of the mononuclear phagocyte series 
and placental cells (17). The in vitro observation that 
one colony-stimulating factor can affect the number 
and possibly the affinity of receptors for another may 
have implication for the proposed use of these factors in 
combination in the clinical setting (9). For instance, 
some solid tumor cell lines express receptors for GM- 
CSF and G-CSF, and endothelial cells interact with 
GM-CSF via receptors as well as having the ability to 
produce colony-stimulating factors (18, 19). The phys- 
iologic importance of the interaction of growth factors 
with nonhematopoietic tissue remains unknown. Stud- 
ies employing either GM-CSF or G-CSF have led to 
observations documenting a lack of effect on in vitro 
clonogenic growth of cell lines derived from solid tu- 
mors (19); furthermore no acceleration of solid tumor 
























factors. The myeloid growth factors hold great promise 
for numerous clinical applications. Clinical trials of 
GM-CSF and G-CSF have been conducted in the con- 
text of neutropenia associated with AIDS (201, chemo- 
therapy-induced neutropenia (211, autologous bone 
marrow transplantation (221, myelodysplasia (23, 241, 
and aplastic anemia (25). Additionally, G-CSF has 
been shown to benefit patients with congenital, idio- 
pathic, and cyclic forms of neutropenia in Phase I/II 
trials (26-30). 
In November of 1988 we began an open-label, ran- 
domized Phase III trial of r-methionyl human granulo- 
cyte-colony-stimulating factor (r-metHuG-CSF) in 
which 41 patients with severe chronic neutropenia 
were enrolled at the University of Michigan as part of 
a larger national study. Patients with diagnoses of con- 
genital, cyclic, and idiopathic neutropenia with histo- 
ries of recurrent infections were evaluated. Forty-one 
such patients had a prestudy ANC of <500/mm3. The 
primary objective of the trial was to evaluate the abil- 
ity of this G-CSF to increase the ANC to >1500/mm3. 
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(shares homology to GM-CSF, 
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A secondary objective was to evaluate the variables 
associated with infection-related morbidity in severe 
chronic neutropenia. G-CSF treatment consisted of 1 
month of dose titration followed by 4 months of treat- 
ment at an optimal dose. Patients were randomized to 
either immediate treatment with G-CSF or 4 months of 
observation consisting of daily documentation of fe- 
vers, infections, and antibiotic usage followed by 
G-CSF treatment. To understand the benefits of treat- 
ment it is necessary to review aspects of the pathophys- 
iology of each of the three disease categories. 
CYCLICNEUTROPENIA 
Cyclic neutropenia is estimated to affect approxi- 
mately 300 to 400 patients in the United States. It is 
characterized by regularly recurrent episodes of severe 
neutropenia (Tables 3 and 4). These episodes occur ap- 
proximately every 18 to 21 days and last 6 to 10 days 
(30). At the nadir circulating neutrophil counts typi- 
cally fall below 200/mm3. Blood lymphocytes and plate- 
lets frequently cycle from normal to above-normal lev- 
els, whereas monocytes and reticulocytes cycle from 
above-normal to below-normal levels. The blood mono- 
cyte count is typically elevated at the nadir of the neu- 
trophil count. 
Cyclic neutropenia remains a disorder of uncertain 
etiology. It occurs with increased frequency among 
family members. Approximately one-half of the pa- 
tients have a family history in which autosomal dom- 
inant inheritance can be documented. 
The cycling of neutrophils is accompanied by cycling 
of other cellular elements, especially the monocytes 
(30). The monocyte cycles are opposite to neutrophil 
cycles, with low neutrophil counts being accompanied 
by high monocyte counts. The bone marrow exhibits a 
period of intense myelopoiesis that begins with the pe- 
riod of neutropenia in which there appears to be an 
arrest at the promyelocyte or myelocyte stage. In about 
8 to 10 days, a high proportion of mature neutrophils 
and a paucity of early neutrophil precursors are noted, 
suggesting the operation of a regulatory negative feed- 
back loop (31). A well-defined etiology has not been 
established. Potential sites for a defect include the 
hematopoietic stem cell or committed progenitors, the 
accessory cells producing human regulatory factors 
TABLE3 
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such as GM-CSF and G-CSF, and the hematopoietic 
microenvironmental substructure including the extra- 
cellular matrix components. In addition, the produc- 
tion on a cyclical basis of an inhibitor of ~anulopoiesis 
could account for periodic oscillations in the blood neu- 
trophil count. Sequential bone marrow morphologic 
changes in patients with cyclic neutropenia and find- 
ings after bone marrow transplantation both in hu- 
mans and in grey collie dogs are consistent with the 
presence of a defect in granulopoietic progenitor cells 
(32). Although the pathophysiology is not clear-cut for 
most cases of cyclic neutropenia, accumulating evi- 
dence indicates that the defect lies either in altered 
sensitivity of myeloid progenitor cells to growth factors 
or in defective regulation of granulopoiesis by acces- 
sory cells. 
The onset of cyclic neutropenia occurs early in child- 
hood; more than half the cases are diagnosed by the age 
of 5. Recurrent episodes of neutropenia are noted every 
18 to 20 days. As the neutrophil count begins to fall, 
patients often note anorexia and malaise. Initially, 
during the first 1 to 3 days of neutropenic episodes, the 
patients are listless and irritable and may exhibit low- 
grade fever, swelling of the lips, and pallor as the neu- 
trophil count reaches its nadir. During the next phase 
of 1 to 3 days, aphthous ulcers of the buccal mucosa, 
lips, tongue, and pharynx develop, often accompanied 
by tender cervical adenopathy. During the neutropenic 
period, skin infections often occur and infections of a 
superficial cut or abrasion with or without lymphangi- 
tis are noted. Chronic gingivitis and dental caries are 
common. Subcutaneous abscesses may occur in the 
neck, axilla, or groin with associated suppurative lym- 
phangitis. Pneumonia with or without abscess forma- 
tion is noted occasionally. Abdominal pain associated 
with diarrhea sometimes occurs during the neutro- 
penic episodes and warrants attention because of the 
possibility that it portends underlying mucosal injury 
with the possibility of resultant bacteremia secondary 
to Clostridium infection and peritonitis. The clinical 
course of a given patient may vary considerably despite 
continued cycling of the neutrophil count. Over time 
some patients may progress toward milder forms of the 
illness or develop a more sustained chronic neutrope- 
nia. 
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In order to establish the diagnosis, serial blood 
counts with white blood cell differential counts are es- 
sential. Usually these should be obtained two to three 
times weekly for 8 weeks in order to confirm the neu- 
trophil cycling at 18- to 20-day intervals. Bone marrow 
aspiration produces varying results depending on the 
time of the cycle at which the aspirate is obtained. 
Until recently most treatment efforts either failed or 
were at best marginally successful. These included 
splenectomy, hormone injections, and nutritional sup- 
plements. Certain therapies have produced some ame- 
lioration of the condition in adults. Treatment with 
corticosteroids, especially on an alternate day sched- 
ule, has been noted to alleviate symptoms for some 
patients (32); however, in only one patient have ste- 
roids completely obliterated the cycling (33). In con- 
trast, in our study when G-CSF was administered sub- 
cutaneously at 5 kg/kg in patients with cyclic neutro- 
penia, marked benefit was noted. The cycle length was 
reduced from 18-20 days to 11-13 days (Tables 3 and 
4). The duration of the neutropenia below 200 cells/ 
mm3 was reduced from 8 days to 1 day. Most impor- 
tantly the propensity for recurrent mucositis and in- 
fection was markedly attenuated. In contrast, use of 
GM-CSF has failed to induce neutrophilia but instead 
induces eosinophilia and monocytosis (34). 
SEVERE CHRONIC IDIOPATHIC NEUTROPENIA AND 
SEVERE CHRONIC CONGENITAL NEUTROPENIA 
The severe chronic neutropenic disorders are com- 
posed of a potpourri of abnormalities associated with 
variable clinical presentations (Table 5). The patho- 
physiology and specific etiologies of many of these con- 
ditions are poorly understood. Patients with severe 
chronic idiopathic neutropenia and various forms of 
severe congenital neutropenia have neutrophil counts 
frequently below 500/mm3. Quite commonly a periph- 
eral monocytosis is observed; somewhat less often, pe- 
ripheral eosinophilia is present (35). As a result, pa- 
tients tend to have frequent, sometimes life- 
threatening, problems with infections. In general, 
TABLE 5 







neutropenia X-linked agammaglobulinemia 
Vitamin B,, or folate Dysgammaglobulinemia 
deficiencies Glycogenosistype IB 
Drug-induced hypersplenism Cartilage-hair hypoplasia 
syndrome 
Dyskeratosis congenita 
“Lazy leukocyte” syndrome 
Chediak-Higashi syndrome 
patients wit.h the lowest neutrophrl county fii1t.t. il‘i Ii: 
tend to have t,he greatest, number of problems and :I: 
fections and are considered to have severe neutropeniki 
In contrast to severe chronic idiopathic neutropenia 
there is a disorder sometimes referred to as chrome- 
benign neutropenia. This condition is characterized by 
a variable degree of neutropenia. Patients with chronic 
benign neutropenia may present in infancy and thr~ 
condition may persist for months to years ! 36:. Somt- 
patients demonstrate resolution over time: this is pay- 
titularly true for younger children who are Srequently 
found to have immune neutropenia of infancy : 37 1. in 
some instances, chronic benign neutropenia may he ge- 
netically transmitted as an autosomal gene such as !s 
found in Yemenite Jews 138). The bone marrow aspi. 
rate typically reveals normal to increased numbers t.>i 
neutrophils that appear normal by electron mitr!;- 
scopic examination. Employment of progenitor assays 
measuring granulocyte and monocyte growth results 
in normal numbers of mature colonies. In general. the 
patients lacking antineutrophil antibodies when chal- 
lenged with intravenous corticosteroids are usually 
able to mobilize neutrophils from the bone marrow re- 
serve pool, which likely accounts for their ability t:-I 
mount an appropriate inflammatory response during 
infection (39). Thus, patients with chronic benign neu.- 
tropenia do not require treatment with G-CSF. In ~011. 
trast to severe chronic idiopathic neutropenia, there is 
no published experience with the use of G-CSF in thr 
treatment of drug-induced I nonchemotherapy i or inr - 
mune-mediated neutropenia. 
Patients with severe chronic idiopathic neutropenla 
or severe congenital neutropenia, as noted previously, 
are predisposed to serious infections including the skin 
(furuncles, cellulitis,, mucosa (oral, gingival. intesti- 
nal), the lungs (penumonia), the liver iabscessesl, the 
ears (otitis media!, and the blood (septicemia) (351. 
Common infectious organisms which are encountered 
include Staphylococcus aureus, Escherichin co/i. and 
Pseudomonas species in the skin, Streptococcus pnerr. 
moniae and Pseudomonas species in the ear, and S 
aureus and E. coli in the lung. A bone marrow aspirate 
contains variable numbers of myeloid precursors. In 
myelokathexis, bone marrow aspiration reveals my- 
eloid hyperplasia, binucleated myelocytes, and hyper- 
segmented neutrophils with strandlike intra.nuclear 
bridges, pyknotic nuclei. and increased cytoplasmic 
vacuolization. In the “lazy leukocyte” syndrome. bone 
marrow aspiration reveals myeloid hyperplasia with 
maturation through the band or segmented form. 
Other acquired and congenital disorders may be re- 
vealed on bone marrow aspiration to have normal to 
increased numbers of promyelocytes with markedly de- 
creased numbers of band and segmented cells or t,o 
have reduced numbers of early myeloid precursors. In 
contrast to those patients with chronic benign neutro- 
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penia, patients with symptomatic infectious complica- 
tions fail to raise their circulating neutrophil count 
when challenged with intravenous corticosteroids. 
In this heterogeneous group of patients, the most 
promising medical therapy is the employment of 
G-CSF to promote granulopoiesis, thereby elevating 
the circulating neutrophil count. It appears that most 
patients with severe chronic neutrophenia will respond 
to G-CSF with a dramatic rise in the peripheral neu- 
trophil count. Administration of 3-5 pg/kg of G-CSF 
once per day subcutaneously is often sufficient to raise 
the circulating neutrophil count. In our own series, two 
patients with large granular lymphocyte-mediated 
neutropenia with evidence of monoclonal T-cell gene 
rearrangement responded to the administration of 
G-CSF in spite of demonstrable suppressor activity in 
vitro to CFU-GM development by their peripheral 
blood T l~phocy~s. In contrast, the only patient in 
our series who failed to respond with a normalization of 
circulating neutrophils was an adolescent who devel- 
oped large granular lymphoc~e-mediated neutropenia 
following a bout with infectious mononucleosis. The 
latter patient had evidence of a polyclonal T-cell gene 
rearrangement in her circulating T lymphocytes. Of 
interest, one patient with congenital agammaglobu- 
linemia developed severe chronic neutropenia at age 5. 
Amelioration of his recurrent infections was accom- 
plished by the administration of both intravenous im- 
mune globulin and G-CSF with restoration of normal 
IgG levels and circulating neutrophil counts, respec- 
tively. 
SEVERECONGENITALAGRANULOCYTOSIS 
Initially described in Sweden by Kostmann in 1956, 
infantile genetic agranulocytosis was characterized by 
severe neutropenia at birth, frequent infections, in- 
creased risk of early death, and an autosomal recessive 
inheritance (40). In the United States, it is highly un- 
usual to have more than one affected sibling with the 
disorder and thus inheritance appears to be sporadic. It 
is characterized by an ANC! usually ~200/mm3, arrest 
of the bone marrow myeloid cells at the promyelocyte- 
myelocyte stage, and early onset of bacterial infections 
within the first month of life. It represents a unique 
subset of the congenital forms of neutropenia in which 
clinical onset of infection is frequently later than the 
first few months of life and bone marrow arrest at the 
promyelocyte stage is unusual. The prevalence of se- 
vere congenital a~anuloc~osis in the United States, 
based on our experience in Michigan, is 300 to 400 
patients. Most troublesome to the patients is the devel- 
opment of chronic gingivitis and the loss of teeth if the 
patients survive into adolescence. These patients are 
the most severely affected in terms of their propensity 
to develop recurrent infections of mucous membranes 
and gums at an early age. Skin infections and the de- 
velopment of deep-seated abscesses, such as in the 
liver, and recurrent pneumonias are common prob- 
lems Frequently these patients will develop bron- 
chiectasis which in the past has led to pneumonectomy. 
Often this was a fatal disorder with death occurring 
within the first two decades of life. 
On bone marrow examination the aspirate reveals 
arrest at the promyelocyte-myelocyte stage of devel- 
opment with increased numbers of eosinophils, lym- 
phocytes, plasma cells, and monocytes noted. Little is 
known about the pathophysiology of this disorder. 
However, recent evidence would suggest that the ab- 
normality may reside in G-CSF receptors or alterna- 
tively in receptor coupling leading to functional re- 
sponses. Review of our own patients’ histories indicates 
that at times of severe infections, such as lobar pneu- 
monia or hepatic abscesses, the patients are able to 
transiently normalize their circulating neutrophil 
counts. Indeed in one of our patients with a docu- 
mented liver abscess at the time of presentation we 
found elevated levels of G-CSF (500 pglml). Normally 
circulating G-CSF is not found in the serum of these 
patients. Additionally, we have observed that, upon 
addition of IL-l to bone marrow fibroblasts derived 
from these patients, G-CSF is released into the super- 
natant. These studies indicate that patients are able to 
make G-CSF and suggest that the defect is not a lack of 
this growth factor but again may reside with abnor- 
malities of its cell surface receptor. Further evidence 
supporting this hypothesis is provided by the observa- 
tion that, when circulating neutrophils are produced 
following the administration of G-CSF to these pa- 
tients, the cells are lacking normal amounts of the CR3 
receptor and the FcRIII receptor (27). These studies 
again suggest abnormalities present in the membrane 
of the neutrophils of severe congenital agranulocytic 
patients. 
Treatment of severe congenital neutropenia with 10 
p.g/kg of G-CSF subcutaneously daily corrects the neu- 
tropenia and decreases the occurrence of acute infec- 
tions. A~inistration of G-CSF leads to maturation of 
the postmitotic pool, increased numbers of neutrophils, 
and increased cellularity of the bone marrow (Fig. 1). 
Treatment is also associated with marked improve- 
ment in dental hygiene, including elimination of gin- 
givitis, aphthous ulcers, and bleeding gums (27). How- 
ever, in those patients showing evidence of varying 
degrees of interdental alveolar bone loss, G-CSF treat- 
ment did not reverse destructive changes in the alve- 
olar bone. It is apparent that restoration of normal 
neutrophil numbers coincides with recovery of gingival 
tissues in this group of patients. Observations indicate 
that host neutrophils are protective and retain func- 
tion, allowing them to deal with localized bacterial in- 
fections within peridontal tissue. Normally in those 
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FIG. 1. Effects of G-CSF on bone marrows of severe congenital neutropenia patients. 
patients with documented liver abscesses, restoration 
of the circulating neutrophil count leads to resolution 
of the liver abscesses. Again, these studies would sug- 
gest that the neutrophils are sufficiently functional in 
severe congenital agranulocytosis to protect the host. 
CONCLUSION 
Similar to the patients with cyclic neutropenia, pa- 
tients with severe congenital agranulocytosis fail to 
respond with an increase in their ANC but develop 
eosinophilia and monocytosis following the adminis- 
tration of GM-CSF (41,421. Often the untoward rise in 
monocyte count and eosinophil count following GM- 
CSF administration is accompanied by fever and cap- 
illary leak syndrome (e.g., pericardial and pleural ef- 
fusion and ascites). However, these same patients will 
respond to G-CSF administration. 
The primary toxicities associated with the adminis- 
tration of G-CSF have been minimal. Usually many of 
the patients will develop bone pain, probably second- 
ary to expansion of the bone marrow with the initial 
administration of the drug. Bone pain responds to anti- 
inflammatory drugs and does not require cessation of 
treatment. Other patients have developed morbilli- 
form rashes, secondary thrombocytopenia, or mild 
splenomegaly. In those patients who developed throm- 
bocytopenia, cessation of the drug is frequently re- 
quired, but G-CSF can be administered later. In- 
creased leukocyte alkaline phosphatase levels, serum 
lactate dehydrogenase levels, and serum uric acid lev- 
els have been noted. The benefits of G-CSF therapy are 
multiple and include fewer infections, less chronic in- 
flammation, more energy and activity, and finally bet- 
ter work and school performance. Without doubt this 
drug has a most profound effect in improving the life of 
numerous patients with varying forms of severe 
chronic neutropenia and warrants use in this group of 
patients. 
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